Chronic Obstructive Pulmonary Disease Therapeutic H1 Pipeline

Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Chronic Obstructive Pulmonary Disease (COPD).
- A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Get Report Details @ http://www.rnrmarketresearch.com/chronic-obstructive-pulmonary-disease-copd-pipeline-review-h1-2013-market-report.html

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Inquiry For Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=86247

Table of Content

Table of Contents 2
Introduction 7
Chronic Obstructive Pulmonary Disease (COPD) Overview 8
Therapeutics Development 9
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics under Development by Companies 11
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 21
Mid Clinical Stage Products 22
Early Clinical Stage Products 23
Discovery and Pre-Clinical Stage Products 24
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Products under Development by Companies 25
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Products under Investigation by Universities/Institutes 39
Companies Involved in Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Development 40
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 137
Drug Profiles 144
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Drug Profile Updates 421
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Discontinued Products 488
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Dormant Products 494
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 505
Appendix 512